Neuromod developers ENeura said yesterday it closed a $17 million Series D round to help support its sTMS transcranial magnetic stimulation system designed for the acute treatment and prevention of migraines.
Funding in the round was led by Camden Partners Nexus, the Baltimore-based company said.
Proceeds raised in the round will help support continued commercial expansion of the sTMS mini neuromodulation device, which won FDA clearance last year and has since been launched in the US.
“In the past, migraine patients in the U.S. have had to depend on combinations of pharmaceutical products, each with potentially unpleasant side-effects, to both treat and prevent migraine. With this round of investment led by Camden Partners, we will be able to offer patients access to a safe, effective and cost-effective treatment and preventative for migraine headache,” prez & CEO David Rosen said in a press release.
ENeura’s sTMS system uses a single-pulse TMS to induce mild electrical currents that can depolarize neurons in the brain, which is thought to interrupt the abnormal hyperactivity associated with migraine.
“eNeura is establishing the market for non-invasive treatment and prevention of migraine headache through sTMS therapy. Neuromodulation is the next great advancement in migraine treatment and prevention and we are pleased to have the opportunity to support eNeura’s commercial efforts to expand sTMS access for patients,” Camden Partners Nexus managing partner Jacob Vogelstein said in a prepared statement.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.